Modern specialty oncology medications—particularly highly individualized cellular therapies, advanced chimeric antigen receptor T-cell treatments, and ultra-rare biomarker-targeted gene therapies—frequently command list prices running into several hundred thousand dollars per course of treatment. The exact pricing depends on manufacturing complexities, single-dose administration models, and specialized clinical delivery requirements managed across specialized cancer centers.